TP53-R175H enhances FOXH1-driven transcriptional programs, promoting self-renewal and cell plasticity, resulting in leukemic transformation and conferring cancer cells the ability to dynamically adapt their phenotype under virtually any type of therapeutic pressure [42]. The gene discussed is TP53; the disease is cancer.